Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Mithra Pharmaceuticals  /  Mithra 2023. The Rise of the Phoenix.

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Mithra Pharmaceuticals BRU:MITRA.BL, BE0974283153

  • 0,224 19 apr 2024 17:36
  • -0,009 (-3,86%) Dagrange 0,221 - 0,232
  • 63.556 Gem. (3M) 380,9K

Mithra 2023. The Rise of the Phoenix.

2.521 Posts
Pagina: «« 1 ... 35 36 37 38 39 ... 127 »» | Laatste | Omlaag ↓
  9. forum rang 8 Leefloon 14 maart 2023 10:16
    quote:

    Kompas schreef op 14 maart 2023 09:42:

    Kunnen we niet meer van die KV's krijgen? Koers loopt voorlopig lekker terug op ;-)
    Aan KV's geen gebrek: live.euronext.com/nl/resources/notice...

    Koersen terug bij af komt vaker voor bij een zeer hoge, richtingneutrale volatiliteit. Ook daaraan dezer dagen geen gebrek.
  13. Down-up 14 maart 2023 23:11
    Wederom een klein half-miljoeneke aandelekes erbij! T’is een gewoonte aan’t worden….

    14-03-2023 PRESS RELEASE Regulated information
    Conversion of a portion of the Highbridge/Whitebox loans Information on the total number of voting rights (denominator)
    Liege, Belgium, 14 March 2023 – 17:45 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the "Company" or "Mithra"), a company dedicated to Women’s Health, today announces that, following the first and second drawdowns by the Company under the loan facility concluded with funds managed by Highbridge Capital Management, LLC ("Highbridge") and funds managed by Whitebox Advisors, LLC ("Whitebox", and together with Highbridge, each a “Lender”), another portion of the loans was contributed in kind by Highbridge against the issuance of new shares.
    On 8th August 2022, the Company and the Lenders entered into a three-year term senior secured convertible facilities agreement for an amount of up to EUR 100 million, which can be drawn in three tranches. The first tranche of EUR 50 million was drawn upon signing of the agreement; the second tranche of EUR 25 million was drawn on 31st October 2022.
    Following the first and second drawdowns, another portion of the loans (including accrued interest, as relevant, and an option payment amount) was contributed in kind for an aggregate amount of EUR 1,854,570.72 through the issuance of 482,528 new shares at an issue price of ca. EUR 3.84 per share. Following the last contribution in kind, the outstanding principal amount of the loans already drawn is EUR 48,860,161.29.
    In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, following this capital increase’s completion Mithra now has 57,073,622 outstanding shares carrying voting rights (against 56,591,094 outstanding shares carrying voting rights previously).
    Therefore, Mithra publishes the following updated information:
    • Capital: EUR 41.783.378,35
    • Total number of securities carrying voting rights: 57,073,622 (all ordinary shares)
    • Total number of voting rights (= denominator): 57,073,622 (all relating to ordinary shares)
    • Number of outstanding rights to subscribe to securities carrying voting rights:
    o Pursuant to the share option plan of 5 November 2018: 1,394,900 subscription rights giving right to 1,394,900 ordinary shares
    o Pursuant to the warrant plan of 22 July 2020: 690,000 subscription rights giving right to 720,571 ordinary shares
    o Pursuant to the warrant plan of 7 September 2020: 300,000 subscription rights giving right to 313,292 ordinary shares
    o Pursuant to the share option plan of 20 November 2020: 390,717 subscription rights giving rise to 390,717 ordinary shares
  14. forum rang 4 FORT1944 14 maart 2023 23:14
    quote:

    Sigaar en Cognac schreef op 14 maart 2023 22:05:

    FC de kampioenen moet nu echt de duimen leggen… want geen grotere soap dan deze.

    Het aantal uitstaande aandelen, de perspectieven, de intrinsieke waarde… What a mess.
    er bestaan nog andere praatbarakken waar ge terecht kunt met Uw prietpraat maar verdoet hier niet langer Uw tijd:)
  15. Biokloot 15 maart 2023 06:36
    Ja lap , weer wat prietpraat voor de realisten : Conversion of a portion of the Highbridge/Whitebox loans
    Information on the total number of voting rights (denominator)

    Liege, Belgium, 14 March 2023 – 17:45 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the "Company" or "Mithra"), a company dedicated to Women’s Health, today announces that, following the first and second drawdowns by the Company under the loan facility concluded with funds managed by Highbridge Capital Management, LLC ("Highbridge") and funds managed by Whitebox Advisors, LLC ("Whitebox", and together with Highbridge, each a “Lender”), another portion of the loans was contributed in kind by Highbridge against the issuance of new shares.

    On 8th August 2022, the Company and the Lenders entered into a three-year term senior secured convertible facilities agreement for an amount of up to EUR 100 million, which can be drawn in three tranches. The first tranche of EUR 50 million was drawn upon signing of the agreement; the second tranche of EUR 25 million was drawn on 31st October 2022.

    Following the first and second drawdowns, another portion of the loans (including accrued interest, as relevant, and an option payment amount) was contributed in kind for an aggregate amount of EUR 1,854,570.72 through the issuance of 482,528 new shares at an issue price of ca. EUR 3.84 per share. Following the last contribution in kind, the outstanding principal amount of the loans already drawn is EUR 48,860,161.29.
2.521 Posts
Pagina: «« 1 ... 35 36 37 38 39 ... 127 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Mithra laat aandeelhouders schrikken

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Mithra Pharmaceuticals Nieuws

  1. 08 mrt AEX blijft nog even op recordjacht in aanloop naar banenrapport VS 1
  2. 08 mrt Lagere omzet Mithra ondanks hogere productomzet
  3. 05 mrt Mithra zet zichzelf in de etalage
  4. 30 nov Mithra ontvangt feedback van Amerikaanse FDA
  5. 11 sep Mithra focust op Estelle en Donesta
  6. 28 aug Mithra rondt aandelenplaatsing af
  7. apr '23 Mithra presenteert nieuwe CEO
  8. mrt '23 Flinke omzetstijging voor Mithra 3
  9. feb '23 Mithra werkt samen met Duits VaRi Bioscience
  10. dec '22 Degroof Petercam: Mithra stelt teleur met partner voor Donesta 2

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!